Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.

Strukova EN, Smirnova MV, Vostrov SN, Lubenko IY, Firsov AA, Zinner SH, Portnoy YA.

Int J Antimicrob Agents. 2009 Mar;33(3):251-4. doi: 10.1016/j.ijantimicag.2008.09.006. Epub 2008 Dec 17.

PMID:
19095420
2.

Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.

Lubenko IY, Strukova EV, Smirnova MV, Vostrov SN, Portnoy YA, Zinner SH, Firsov AA.

J Antimicrob Chemother. 2008 Nov;62(5):1065-9. doi: 10.1093/jac/dkn288. Epub 2008 Jul 17.

PMID:
18635520
3.

Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.

Firsov AA, Lubenko IY, Smirnova MV, Strukova EN, Zinner SH.

Antimicrob Agents Chemother. 2008 Jun;52(6):1924-8. doi: 10.1128/AAC.01371-07. Epub 2008 Mar 31.

4.

Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline.

Zinner SH, Gilbert D, Lubenko IY, Greer K, Firsov AA.

J Antimicrob Chemother. 2008 Mar;61(3):629-35. doi: 10.1093/jac/dkm542. Epub 2008 Feb 1.

PMID:
18245198
5.
6.

Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.

Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH.

J Antimicrob Chemother. 2006 Dec;58(6):1185-92. Epub 2006 Oct 5.

PMID:
17028094
7.
8.
9.

Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.

Firsov AA, Alferova IV, Smirnova MV, Lubenko IY, Portnoy YA, Zinner SH.

Int J Antimicrob Agents. 2005 May;25(5):409-13.

PMID:
15848296
10.

Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.

Zinner SH, Vostrov SN, Alferova IV, Lubenko IY, Portnoy YA, Firsov AA.

Int J Antimicrob Agents. 2004 Aug;24(2):173-7.

PMID:
15288317
11.

ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.

Firsov AA, Vostrov SN, Lubenko IY, Arzamastsev AP, Portnoy YA, Zinner SH.

J Antimicrob Chemother. 2004 Jul;54(1):178-86. Epub 2004 Jun 9.

PMID:
15190041
12.
13.
14.
15.

In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.

Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH.

Antimicrob Agents Chemother. 2003 May;47(5):1604-13.

16.

Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters.

Firsov AA, Zinner SH, Lubenko IY, Portnoy YA, Vostrov SN.

Chemotherapy. 2002;48(6):275-9.

PMID:
12673102
17.

Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model.

Portnoy YA, Vostrov SN, Lubenko IY, Zinner SH, Firsov AA.

Int J Antimicrob Agents. 2002 Sep;20(3):201-5.

PMID:
12385699
18.

AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.

Firsov AA, Zinner SH, Vostrov SN, Portnoy YA, Lubenko IY.

J Antimicrob Chemother. 2002 Oct;50(4):533-9.

PMID:
12356798
19.
20.

The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.

Zinner SH, Firsov AA, Gilbert D, Simmons K, Lubenko IY.

J Antimicrob Chemother. 2001 Dec;48(6):821-6.

PMID:
11733466
21.

Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.

Zinner SH, Vostrov SN, Lubenko IY, Portnoy YA, Cornaglia G, Firsov AA.

Diagn Microbiol Infect Dis. 2001 Aug;40(4):167-71.

PMID:
11576789
22.
23.

Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.

Firsov AA, Zinner SH, Lubenko IYu, Vostrov SN.

Int J Antimicrob Agents. 2000 Dec;16(4):407-14.

PMID:
11118849
24.

Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.

Firsov AA, Lubenko IY, Vostrov SN, Kononenko OV, Zinner SH, Portnoy YA.

J Antimicrob Chemother. 2000 Nov;46(5):725-32.

PMID:
11062191
25.
26.

Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.

Firsov AA, Vasilov RG, Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH.

J Antimicrob Chemother. 1999 Apr;43(4):483-90.

PMID:
10350376

Supplemental Content

Loading ...
Support Center